Cefpirome–vancomycin combination in methicillin-resistant Staphylococcus aureus infection  by Raymond, J. et al.
C o r r e s p o n d e n c e  733 
Michael Barnham'*, Nigel Weightman' 
Department of Microbiology, 
Harrogate General Hospital, 
Harrogate, 
North Yorkshire GH2 7ND, UK; 
'Department of Microbiology, 
Friarage Hospital, 
Northallerton, 
North Yorkshire, UK 
*Tel: +44 1423 553077 Fax: +44 1423 553208 
References 
1. Tande D, Picard B, Brittany Hospital Laboratories. Evaluation of 
the E-test for routine testing of the susceptibility of Streptococcus 
pneumoniae to henzylpenicillin, amoxicillin and cefotaxime. Clin 
Microbiol Infect 1997; 3: 474-9. 
2. Hoogkamp-Korstanje JAA, Dirks-Go SIS, Kahel P, et al. 
Multicentre in-vitro evaluation of the susceptibility of Strepto- 
coccus pneumoniae, Haemopkilus infuenzae and Moraxella catarrkalis 
to ciprofloxacin, clarithromycin, co-amoxiclav and sparfioxacin. 
J Antimicrob Chemother 1997; 39: 411-14. 
3. Jorgensen JH,  Howell AW, Maher L. Quantitative antimicrobial 
susceptibility testing of Haemopkilus ir$uerrrae and Streptococcus 
pneumoniae by using the E-test. J Clin Microhiol 1991; 29: 
4. Enting R H ,  Spanjaard L, van de Beek D, Hensen EF, de Ghans 
J, Dankert J. Antimicrobial susceptibility of Haemopkilus injuenrae 
and Streptococcus pneumorziae isolates causing meningitis in the 
Netherlands, 1993-1994. J Antimicrob Chemother 1996; 38: 
5. Scheel 0, Lyon DJ, Tsang DNC, Cheng AFB. Comparison 
of E-test with agar dilution for determining susceptibility of 
Streptococcus pneumoniae to penicillin. Eur J Clin Microbiol Infect 
Dis 1997; 16: 608-10. 
6. Working Party on Antibiotic Sensitlvity Testing of the British 
Society for Antimicrobial Chemotherapy. Supplementary report 
to A guide to sensitivity testing. J Antimicrob Chemother 1996; 
109-14. 
777-86. 
38: 1103-5. 
Cefpirome-vancomycin combination in 
methicillin-resistant Staphylococcus aureus infection 
Clin Microbiol Infect 1998; 4: 733-734 
In the treatment of severe staphylococcal infections, 
especially in neutropenic patients or when multiple 
antibiotic resistance is present, vancomycin is often 
used with other antistaphylococcal agents such as 
rifampicin, fosfomycin or fusidic acid. In a previous 
study, we described the in vitro bactericidal activity 
of the cefpirome-vancomycin combination against 
both methicillin-susceptible and methicillin-resistant 
Staphylococcus aureus (MRSA) and coagulase-negative 
Staphylococcus strains [l]. 
An 8-year-old girl, who had cystic fibrosis 
diagnosed during the first year of life, had pulmonary 
colonization with a homogeneously methicillin-resistant 
Staphylococcus aureus strain. This had been present for a 
year at counts of 10z-lO1l CFU/mL in monthly sputum 
specimens, with consistent susceptibility to antibiotics. 
Pseudomonas aeruginosa was never detected. The girl had 
been treated for 6 months with the following com- 
binations: (1) co-trimoxazole (30 mg/kg per day) plus 
fosfomycin (80 mg/kg per day) plus vancomycin 
(80 mg/kg per day) for 1 month; (2) vancomycin plus 
cefotaxime (100 mg/kg per day) for 3 weeks; (3) 
pristinamycin (1 60 mg/kg per day) plus aerosolized 
vancomycin (750 mg per day) for 2 months; (4) vanco- 
mycin plus imipenem (100 mg/kg per day) for 3 weeks; 
and (5) pristinamycin (160 mg/kg per day) for 6 weeks. 
Vancomycin concentrations in serum were regularly 
monitored. With this treatment, the Staphylococcus 
anreus count in sputum decreased to lo2 CFU/mL but 
the strain was never eradicated. During January 1997, 
the patient experienced a new febrile episode with 
a right inferior lobe atelectasis and hypoxemia. The 
C-reactive protein concentration was 77 mg/L (normal 
values: 0-8 mg/L). Blood cultures remained sterile. 
Sputum cultures revealed the presence of three different 
bacterial isolates: an MRSA isolate (5 X lo6 CFU/mL), 
a derepressed mutant of Enterobacter cloacae (7 X 
lo5 CFU/mL), a P-lactamase-producing strain of 
Haemophilus infuenzae (4 X 106 CFU/mL) and Asper- 
gillusfurnigatus (10 CFU/mL). The E. cloacae strain was 
susceptible to ce$irome, cefepime, imipenem, colistin, 
quinolones and cotrimoxazole, whereas the S. aureus 
isolate was resistant to all these antibiotics. The clinical 
significance of A. furnigatus was confirmed by positive 
serology. 
We performed a time kill assay of the in vitro effect 
of cefpironie-vancomycin against the Staphylococcus 
aureus isolate, using the methods previously described 
[l]. The minimum inhibitory concentrations (MICs) 
were 64 mg/L of cefpirome and 1 mg/L of vanco- 
mycin. In the time kill assay, the lowest combination 
exhibiting a bactericidal effect (>3 loglo CFU/mL 
reduction) was 8 mg/L of cefpirome (0.125 X MIC) and 
1 mg/L (1 XMIC) of vancomycin (Table 1). This 
cefpirome concentration can be achieved in the lungs 
We decided to treat the girl with a combination of 
intravenous cefpirome 100 mg/kg per day and vanco- 
mycin 40 mg/kg per day in three divided doses. 
Two days later, the fever had decreased and sputum 
culture revealed lo2 CFU/mL of Staphylococcus aureus, 
10' CFU/mL. of A. furnigatus and absence of E. cloacae. 
O n  day 4, the girl became apyrexial and the C-reactive 
protein concentration was 87 mg/L. At day 15, sputum 
culture showed eradication of Staphylococcus aureus, E .  
cloacae and H .  intuenzae; Stenotrophomonas maltophilia 
P I .  
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Table 1 Results of the time kill study for the isolated strain of Staphylocuccirs aureus: percentage of surviving bacteria 
Concentrations tested (mg/L) Surviving bacteria (“Yo inoculum) 
Vanconiycin Cefpironie 8 h  18 h 24 h 48 h 
1 n 1 1 0 10 100 
2 0 1 1 1 100 
(1 8 100 100 1 on 100 
0 16 ion  I 0  10 1 
0 32 ino  1 0 10 I 
0 64 1 10 1 0 I 0  
(1 128 1 a . n i  <0.01 <O.OI 
1 8 1 1 0  1 0 1 0  
2 8 1 0.1 <0.01 <o.ni 
1 16 I 0.1 0.1 I). 1 
2 16 1 0.01 <0.01 <0.01 
1 32 1 0.1 0.1 (I. 1 
2 32 1 0.01 <0.01 <001 
1 64 1 0.01 0.01 0.1 
2 64 1 4 . 0 1  4 . 0 1  <!J.OI 
wa5 isolated at  106 CFU/niL and A. fumigatus  at 
10’ CFU/mL. The C-reactive protein concentration 
was 8 mg/L. The radiologic findings, however, 
remained unchanged. Vancomycin and cefpirome 
concentrations were determined in serum 1 h after 
infusion, and were 10.2 mg/L and 115 mg/L res- 
pectively. The girl was treated for 3 weeks. Two months 
after the end of treatment, Staphylorocrus aweus and E. 
cloacae had not reappeared and the 0 2  saturation was 
improved (95%). 
The optimal strategy for treating Staphylococcus 
aureus infections is vancomycin combined with other 
antistaphylococcal agents [3] .  Synergy between 
cefpirome and vancomycin against MRSA strains was 
first reported by Seibert et a1 [4]. We demonstrated by 
a time kill method that synergy between the two drugs 
occurred with low cefpirome concentrations which can 
be achieved in serum and most of the tissues even in 
cases of methicillin resistance. With MICs of 64 mg/L 
of cefpirome and 1 mg/L of vancomycin, both drugs 
are bactericidal at  concentrations achieved at the peak 
serum concentrations of 115 mg/L and 10 mg/L 
respectively. However, these concentrations are not 
achieved in lungs or deep tissues, so a bactericidal effect 
at lower concentrations is needed. 
Prediction of the success of therapeutic use of an 
antibiotic combination effective in in vitro studies is not 
preliminary step before human use. However, in 
particular cases, e.g. in mixed infections when standard 
treatment fails to eradicate a pathogen, treatment with 
2 
always accurate, and animal studies are usually a 4 
a new antibiotic combination is justified. In our 
patient, the combination of cefpirome and vancomycin 
was successful in the bacteriological eradication of a 
mixed infection including MRSA and E.  cloacae. 
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